<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04964193</url>
  </required_header>
  <id_info>
    <org_study_id>440/STD/PML/2018</org_study_id>
    <nct_id>NCT04964193</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Cyproterone Acetate and Ethinyl Estradiol in Healthy Female Volunteers</brief_title>
  <official_title>Bioequivalence Study of 2 mg Cyproterone Acetate and 0.035 mg Ethinyl Estradiol in Indonesian Healthy Females</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PT Sydna Farma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PT Pharma Metric Labs</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>PT Sydna Farma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study was conducted to investigate whether 2 mg cyproterone acetate (CPA) and 0.035 mg&#xD;
      ethinyl estradiol (EE) film-coated tablet (Elzsa®) manufactured by PT. Sydna Farma was&#xD;
      bioequivalent to its reference product, Diane®-35 sugar-coated tablet manufactured by Bayer&#xD;
      Weimar GmbH, Germany, imported by PT. Bayer Indonesia, Depok, Indonesia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Twenty four healty female subjects were given a single dose of Elzsa® FCT or or Diane®-35&#xD;
      with 240 mL of water. Then the blood samples for CPA and EE were drawn and analyzed using&#xD;
      LCMS/MS. All subjects sample plasma were analyzed for pharmacokinetic evaluation&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 12, 2019</start_date>
  <completion_date type="Actual">September 26, 2019</completion_date>
  <primary_completion_date type="Actual">July 4, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized, single blind, two-period, single dose, crossover study with three weeks washout period in 24 healthy female subjects under fasting condition.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Ratio</measure>
    <time_frame>3 months</time_frame>
    <description>The ratio between test drug and reference drug</description>
  </primary_outcome>
  <primary_outcome>
    <measure>90% confidence intervals</measure>
    <time_frame>3 months</time_frame>
    <description>The two products are considered bioequivalent when the 90% confidence intervals of the cyproterone acetate and ethinyl estradiol geometric mean ratio between test and reference product fall within the range of 80.00-125.00% for AUCt and Cmax.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics parameter</measure>
    <time_frame>3 months</time_frame>
    <description>Maximum plasma concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics parameter</measure>
    <time_frame>3 months</time_frame>
    <description>Area Under Curve from 0 to 72 hours (AUCt)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Drug Use</condition>
  <arm_group>
    <arm_group_label>Elzsa film-coated tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received Elzsa film-coated tablet (2 mg cyproterone acetate + 0.035 mg ethinylestradiol) with 240 mL of water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diane-35 Sugar-coated tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received Diane-35 Sugar-coated tablet ( 2 mg cyproterone acetate + 0.035 mg ethinylestradiol) with 240 mL of water</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elzsa film-coated tablet</intervention_name>
    <description>Administered with 240 mL of water</description>
    <arm_group_label>Elzsa film-coated tablet</arm_group_label>
    <other_name>2 mg cyproterone acetate + 0.035 mg ethinylestradiol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diane-35 Sugar-coated tablet</intervention_name>
    <description>Administered with 240 mL of water</description>
    <arm_group_label>Diane-35 Sugar-coated tablet</arm_group_label>
    <other_name>2 mg cyproterone acetate + 0.035 mg ethinylestradiol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
        The inclusion criteria are healthy female subjects who/with:&#xD;
&#xD;
          -  have read the subject information and signed informed consent documents&#xD;
&#xD;
          -  age 18 - 55 years&#xD;
&#xD;
          -  body mass index between 18-25 kg/m2&#xD;
&#xD;
          -  have a normal electrocardiogram&#xD;
&#xD;
          -  blood pressure within normal range (90-120 mmHg for systolic blood pressure and 60-80&#xD;
             mmHg for diastolic blood pressure)&#xD;
&#xD;
          -  heart rate within normal range (60-100 bpm)&#xD;
&#xD;
          -  with absence of significant disease or clinically significant abnormal laboratory&#xD;
             values on laboratory evaluation, medical history or physical examination during&#xD;
             screening&#xD;
&#xD;
          -  pass hormone screening related to cyproterone acetate and ethinyl estradiol&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
        Any of the following criteria will exclude the subject from the study:&#xD;
&#xD;
          -  those who are pregnant and/or nursing woman.&#xD;
&#xD;
          -  those with history of hypersensitivity to cyproterone acetate and ethinyl estradiol or&#xD;
             other oral contraception or other ingredients in the drugs or a history of serious&#xD;
             allergic reaction to any drug, significant allergic disease, allergic reaction, or&#xD;
             active allergic.&#xD;
&#xD;
          -  those with a history or presence medical condition which might significantly influence&#xD;
             the pharmacokinetic of the study drug, e.g. chronic gastrointestinal disease,&#xD;
             diarrhea, gastric surgery, renal insufficiency, hepatic dysfunction or cardiovascular&#xD;
             disease.&#xD;
&#xD;
          -  those with a history or presence of any coagulation disorder or clinically significant&#xD;
             hematology abnormalities, thrombophlebitis, and thromboembolic disorder.&#xD;
&#xD;
          -  those who are using any medication (prescription or non-prescription drug, food&#xD;
             supplement, herbal medicine, oral contraception, anti-platelet drug), particularly the&#xD;
             medication known to affect the pharmacokinetic of the study drug, within one week&#xD;
             prior to the drug administration day.&#xD;
&#xD;
          -  those who have participated in any clinical study within 3 months prior to the study&#xD;
             (&lt; 90 days).&#xD;
&#xD;
          -  those who have donated or lost 300 ml (or more) of blood within 3 months prior to the&#xD;
             study.&#xD;
&#xD;
          -  those who smoke.&#xD;
&#xD;
          -  those who are positive to HIV, HBsAg, and HCV tests (to be kept confidential).&#xD;
&#xD;
          -  those with a history of drug or alcohol abuse within 12 months prior to screening for&#xD;
             this study.&#xD;
&#xD;
          -  those who are unlikely to comply with the protocol, e.g uncooperative attitude,&#xD;
             inability to return for follow up visits, poor venous access.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>54 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>PT Pharma Metric Labs</name>
      <address>
        <city>Multiple Locations</city>
        <state>Jakarta</state>
        <zip>10520</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <link>
    <url>http://www.ema.europa.eu/en/documents/referral/cyproterone/ethinylestradiol-containing-medicines-article-107i-procedure-prac-assessment-report_en.pdf</url>
    <description>(accessed on Sep 18, 2020)</description>
  </link>
  <link>
    <url>https://resources.bayer.com.au/resources/uploads/PI/file10408.pdf</url>
    <description>(accessed on Sep 18, 2020)</description>
  </link>
  <results_reference>
    <citation>Luque-Ramírez M, Alvarez-Blasco F, Botella-Carretero JI, Martínez-Bermejo E, Lasunción MA, Escobar-Morreale HF. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 2007 Jul;92(7):2453-61. Epub 2007 Apr 10.</citation>
    <PMID>17426085</PMID>
  </results_reference>
  <results_reference>
    <citation>Bhattacharya SM, Jha A. Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome. Fertil Steril. 2012 Oct;98(4):1053-9. doi: 10.1016/j.fertnstert.2012.06.035. Epub 2012 Jul 13.</citation>
    <PMID>22795636</PMID>
  </results_reference>
  <results_reference>
    <citation>Elger W, Beier S, Pollow K, Garfield R, Shi SQ, Hillisch A. Conception and pharmacodynamic profile of drospirenone. Steroids. 2003 Nov;68(10-13):891-905.</citation>
    <PMID>14667981</PMID>
  </results_reference>
  <results_reference>
    <citation>Bitzer J, Römer T, Lopes da Silva Filho A. The use of cyproterone acetate/ethinyl estradiol in hyperandrogenic skin symptoms - a review. Eur J Contracept Reprod Health Care. 2017 Jun;22(3):172-182. doi: 10.1080/13625187.2017.1317339. Epub 2017 Apr 27. Review.</citation>
    <PMID>28447864</PMID>
  </results_reference>
  <results_reference>
    <citation>Speck U, Wendt H, Schulze PE, Jentsch D. Bio-availability and pharmacokinetics of cyproterone acetate-14C and ethinyloestradiol-3H after oral administration as a coated tablet (SH B 209 AB). Contraception. 1976 Aug;14(2):151-63.</citation>
    <PMID>949892</PMID>
  </results_reference>
  <results_reference>
    <citation>Kuhnz W, Staks T, Jütting G. Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles. Contraception. 1993 Dec;48(6):557-75.</citation>
    <PMID>8131397</PMID>
  </results_reference>
  <results_reference>
    <citation>Sedgwick P. Bias in randomised controlled trials: comparison of crossover group and parallel group designs. BMJ. 2015 Aug 7;351:h4283. doi: 10.1136/bmj.h4283.</citation>
    <PMID>26253465</PMID>
  </results_reference>
  <results_reference>
    <citation>Garcia R, Benet M, Arnau C, Cobo E. Efficiency of the cross-over design: an empirical estimation. Stat Med. 2004 Dec 30;23(24):3773-80.</citation>
    <PMID>15580599</PMID>
  </results_reference>
  <results_reference>
    <citation>Sedgwick P. What is a crossover trial? BMJ. 2014 May 9;348:g3191. doi: 10.1136/bmj.g3191.</citation>
    <PMID>25134118</PMID>
  </results_reference>
  <results_reference>
    <citation>Sedgwick P. Randomised controlled trials: &quot;within subject&quot; versus &quot;between subject&quot; designs. BMJ. 2014 Oct 24;349:g6435. doi: 10.1136/bmj.g6435.</citation>
    <PMID>25954990</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 14, 2021</study_first_submitted>
  <study_first_submitted_qc>July 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2021</study_first_posted>
  <last_update_submitted>July 5, 2021</last_update_submitted>
  <last_update_submitted_qc>July 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cyproterone acetate</keyword>
  <keyword>ethinyl estradiol</keyword>
  <keyword>bioequivalence</keyword>
  <keyword>cross-over design study</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>Indonesian healthy female</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyproterone Acetate</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Cyproterone</mesh_term>
    <mesh_term>Cyproterone acetate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 12, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT04964193/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <pending_results>
    <submitted>July 19, 2021</submitted>
    <submission_canceled>July 23, 2021</submission_canceled>
    <submitted>July 23, 2021</submitted>
    <returned>August 17, 2021</returned>
    <submitted>October 6, 2021</submitted>
    <returned>November 3, 2021</returned>
    <submitted>November 16, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

